To avoid the complications associated with levodopa prolonged usage, other strategies for PD therapy have been developed including DA agonists which exert their pharmacological action by triggering the dopaminergic receptors directly, in addition to COMT and MAO-B inhibitors, which are both responsible for the degradation and metabolism of DA [7]. This evidence concerns the gene MAOB and Parkinson disease.